EMSCO provides services including review of trial design, medical writing, support with essential clinical trial documents, contracts, publications, management and coordination of clinical trials and projects associated with MDS. EMSCO’s multilingual staff has ample experience in the international context and is therefore apt to fulfil these tasks.

One of the major goals of EMSCO is to offer an expert MDS office team to assist, design and review clinical trials in MDS. The team includes a lead KOL, a biostatistician, data collection personnel and management personnel. Furthermore, standardized Clinical Trial Documents and SOPs for MDS trials are created. One of the main goals of EMSCO is to improve the quality and comparability of clinical trials.

Currently running EMSCO trials:


A phase II study evaluating the efficacy and safety of Bemcentinib in patients with MDS or AML failing standard of care therapy
Status: recruiting in France and Germany


Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML)
Status: recruitment completed


Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia
Status: recruitment completed


Multicenter, randomized, double-blind, phase III study of Revlimid® (Lenalidomide) versus Placebo in patients with low risk myelodysplastic syndrome (low and intermediate-1 IPSS) with alteration in 5q and anemia without the need of transfusion
Status: recruitment completed


Single agent JNJ-56022473 in MDS and AML patients failing hypomethylating agent based therapy
Status: prematurely terminated